

Table 1. Primary and secondary outcomes of Study GOG 281/LOGS⁶

Outcome	Trametinib (n=130)	Standard-of- care (n=130)	Hazard ratio (95% CI)
Primary outcome: progression-free survival (follow-up 31 months)			
PFS events (%)	101 (78%)	116 (89%)	
Median PFS (95% CI)	13 months (9.9 to 15)	7.2 months (5.6 to 9.9)	0.48 (0.36 to 0.64) P<0.0001
Secondary outcomes			
Objective response rate	26%	6%	Odds ratio 5.4 (2.4 to 12.2) P <0.0001
Median duration of response (IQR)	13.6 months (7.2 to 19.9)	5.9 months (4.0 to 12.2)	
Overall deaths (%)	51 (39%)	60 (46%)	
Median OS* (95%CI)	37.6 months (32 to NE)	29.2 months (23 to 51.6)	0.76 (0.51 to 1.12) P=0.056
Quality of life	NS	NS	
* OS analysis includes the effect of 88 patients who crossed over to trametinib after disease progression CI: confidence interval; IQR: interquartile range; NE: not evaluable; NS: not significant; OS: overall survival; PFS: progression-free survival;			